Os accionistas de TomoTherapy APROVAM a compra de Accuray
por Brendon Nafziger, DOTmed News Associate Editor | June 09, 2011
TomoTherapy's shareholders approved Accuray Inc.'s buyout in a vote Thursday, according to a statement issued by Accuray.
More than 98 percent of votes cast and 79 percent of outstanding shares were voted in favor of the transaction, Sunnyvale, Calif.-based Accuray said. The deal should close in one or two business days, once customary closing conditions are met.
The mixed cash and stock deal, originally valued at $277 million, was announced in March. At the time, Accuray CEO Euan S. Thompson and TomoTherapy CEO Dr. Frederick A. Robertson discussed the merger and the future potential for the two companies with DOTMed News.
Accuray, which makes the CyberKnife radiosurgery platform, and TomoTherapy, which makes a computed tomography-guided intensity-modulated radiation therapy system, had combined sales of $400 million last year.
More than 98 percent of votes cast and 79 percent of outstanding shares were voted in favor of the transaction, Sunnyvale, Calif.-based Accuray said. The deal should close in one or two business days, once customary closing conditions are met.
The mixed cash and stock deal, originally valued at $277 million, was announced in March. At the time, Accuray CEO Euan S. Thompson and TomoTherapy CEO Dr. Frederick A. Robertson discussed the merger and the future potential for the two companies with DOTMed News.
Accuray, which makes the CyberKnife radiosurgery platform, and TomoTherapy, which makes a computed tomography-guided intensity-modulated radiation therapy system, had combined sales of $400 million last year.
You Must Be Logged In To Post A CommentRegistoO registro é gratuito e fácil. Aproveite os benefícios dos principais produtos novos e inovadores do mundo. Mercado de equipamentos médicos usados. Registrar agora! |
|
